Werewolf Therapeutics (HOWL) Projected to Post Earnings on Thursday

Key Points

• Werewolf Therapeutics is expected to report a Q2 2025 loss of ($0.50) per share on August 14th, following a previous report where it surpassed estimates.
• The company's stock is currently down 1.7%, trading at $1.19, with significant institutional ownership at approximately 64.84%.
• Wedbush has lowered its price target for Werewolf Therapeutics from $8.00 to $6.00, maintaining an "outperform" rating.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.04. On average, analysts expect Werewolf Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Werewolf Therapeutics Stock Down 1.7%

Werewolf Therapeutics stock opened at $1.19 on Thursday. The stock's 50 day moving average price is $1.24 and its 200 day moving average price is $1.15. The company has a market cap of $53.40 million, a PE ratio of -0.71 and a beta of 0.63. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.09 and a quick ratio of 8.09. Werewolf Therapeutics has a 1-year low of $0.60 and a 1-year high of $4.18.

Wall Street Analyst Weigh In

Separately, Wedbush lowered their price target on shares of Werewolf Therapeutics from $8.00 to $6.00 and set an "outperform" rating on the stock in a research note on Friday, May 9th.

Insider Activity

In other news, Director Ra Capital Management, L.P. purchased 162,539 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were acquired at an average price of $0.98 per share, for a total transaction of $159,288.22. Following the acquisition, the director directly owned 6,237,482 shares in the company, valued at approximately $6,112,732.36. The trade was a 2.68% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 23.60% of the company's stock.

Institutional Trading of Werewolf Therapeutics

A hedge fund recently bought a new stake in Werewolf Therapeutics stock. AQR Capital Management LLC purchased a new stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 81,669 shares of the company's stock, valued at approximately $79,000. AQR Capital Management LLC owned approximately 0.18% of Werewolf Therapeutics as of its most recent SEC filing. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.